| Product No | EMEA/H/C/006016 |
|---|---|
| Brand Name | Imjudo |
| Nonproprietary Name | tremelimumab |
| API | Tremelimumab |
| ATC Code | L01FX |
| Indications | Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). |
| Orphan Drug | no |
| Generics | no |
| Marketing Authorization Holder | AstraZeneca AB |
| Status | Authorised(授权) |
| Authorization Date | 2023-02-20 |
| Version | 0 |
| Condition Approval | no |
| Exceptions | no |
| Biosimilar | no |
| Details | 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息) |
Extended Information